2025
SJR Q3
JCR Q3 · 2,1
524 eşleşen makale
SCIE
Dergi ayrıntısı
Journal of Chemotherapy
- Yayıncı
- Taylor and Francis Ltd.
- Ülke
- United Kingdom · Western Europe
- Tür
- journal
- ISSN
-
1120009X19739478
Bütünleşik değerlendirme
Scopus tarafı Scimago SJR; WoS tarafı Master Journal List + JCR/JIF. Kaynaklar ISSN üzerinden eşleştirilir. WoS / JCR metrikleri yalnızca 1997 ve sonrası yıllar için vardır.
WoS / JCR verileri 1997 ve sonrası içindir.
Scopus
Scopus · Scimago
- SJR 0,525
- Quartile Q3
- H-Index 60
- Atıf/yayın 2,07
- Doküman (3y) 221
- Atıf (3y) 438
Clarivate
Web of Science · JCR · 2025
- JCR Q Q3
- JIF 2,1
- 5Y JIF 1,9
- JCI 0,53
WoS indeksleri
- SCIE
Konu sınıflandırması
Kategoriler (SJR)
WoS kategorileri
Yıllık quartile karşılaştırması
Scimago (SJR) tüm yıllar; Clarivate (JCR / JIF / JCI) 1997 ve sonrası. Güncel yıl açık; diğer yıllar kapalıdır.
WoS / JCR verileri 1997 ve sonrası içindir.
| Yıl | SJR Q | JCR Q (1997+) | SJR | JIF (1997+) | 5Y JIF (1997+) | JCI (1997+) | JCI Q (1997+) | H-Index |
|---|---|---|---|---|---|---|---|---|
| 2025 | Q3 | Q3 | 0,525 | 2,1 | 1,9 | 0,53 | Q3 | 60 |
| 2024 | Q3 | Q3 | 0,479 | 1,8 | 1,8 | 0,49 | Q3 | 59 |
| 2023 | Q3 | Q3 | 0,439 | 1,9 | 2 | 0,5 | Q3 | 59 |
| 2022 | Q3 | Q4 | 0,388 | 1,8 | 2 | 0,44 | Q3 | 59 |
| 2021 | Q3 | Q4 | 0,429 | 2,4 | 2,1 | 0,46 | Q3 | 59 |
| 2020 | Q3 | Q4 | 0,515 | 1,7 | 1,8 | 0,48 | Q3 | 59 |
| 2019 | Q2 | Q4 | 0,476 | 1,7 | 1,4 | 0,47 | Q3 | 59 |
| 2018 | — | Q4 | — | 1,6 | 1,5 | 0,46 | Q3 | — |
| 2017 | Q2 | Q4 | 0,483 | 1,5 | 1,5 | 0,4 | Q4 | 59 |
| 2016 | Q2 | Q4 | 0,521 | 1,6 | 1,4 | — | — | 59 |
| 2015 | Q2 | Q4 | 0,512 | 1,3 | 1,1 | — | — | 59 |
| 2014 | Q2 | Q3 | 0,518 | 1,6 | 1,2 | — | — | 59 |
| 2013 | Q3 | Q4 | 0,347 | 1,1 | 1 | — | — | 59 |
| 2012 | Q2 | Q4 | 0,397 | 0,8 | 1 | — | — | 59 |
| 2011 | Q2 | Q4 | 0,462 | 1,1 | 1 | — | — | 59 |
| 2010 | Q2 | Q4 | 0,464 | 1,1 | 1 | — | — | 59 |
| 2009 | — | Q4 | — | 1,2 | 1,1 | — | — | — |
| 2008 | — | Q4 | — | 0,8 | 1,1 | — | — | — |
| 2007 | — | Q4 | — | 0,9 | 1,1 | — | — | — |
| 2006 | — | Q3 | — | 1,4 | — | — | — | — |
| 2005 | — | Q3 | — | 1,1 | — | — | — | — |
| 2004 | — | Q3 | — | 1,1 | — | — | — | — |
| 2003 | — | Q3 | — | 1,1 | — | — | — | — |
| 2002 | — | Q3 | — | 0,8 | — | — | — | — |
| 2001 | — | Q3 | — | 1,3 | — | — | — | — |
| 2000 | — | Q3 | — | 0,9 | — | — | — | — |
| 1999 | — | Q3 | — | 0,8 | — | — | — | — |
| 1998 | — | Q3 | — | 0,7 | — | — | — | — |
| 1997 | — | Q4 | — | 0,3 | — | — | — | — |
JCR kategori quartile geçmişi
Yıla ve kategoriye göre JCR / JCI quartile. 1997 ve sonrası.
WoS / JCR verileri 1997 ve sonrası içindir.
| Yıl | Kategori | Edition | JCR Q (1997+) | JCI Q (1997+) | Sıra |
|---|---|---|---|---|---|
| 2025 | INFECTIOUS DISEASES | SCIE | Q3 | Q3 | 95/141 |
| 2025 | ONCOLOGY | SCIE | Q3 | Q3 | 236/333 |
| 2025 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | Q3 | 240/356 |
| 2024 | INFECTIOUS DISEASES | SCIE | Q3 | Q3 | 95/137 |
| 2024 | ONCOLOGY | SCIE | Q4 | Q3 | 253/328 |
| 2024 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | Q3 | 244/352 |
| 2023 | INFECTIOUS DISEASES | SCIE | Q3 | Q3 | 90/132 |
| 2023 | ONCOLOGY | SCIE | Q3 | Q3 | 234/322 |
| 2023 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | Q3 | 231/354 |
| 2022 | INFECTIOUS DISEASES | SCIE | Q4 | Q3 | 84/96 |
| 2022 | ONCOLOGY | SCIE | Q4 | Q3 | 220/241 |
| 2022 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | Q3 | 231/278 |
| 2021 | INFECTIOUS DISEASES | SCIE | Q4 | Q3 | 78/95 |
| 2021 | ONCOLOGY | SCIE | Q4 | Q3 | 210/245 |
| 2021 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | Q3 | 213/279 |
| 2020 | INFECTIOUS DISEASES | SCIE | Q4 | Q3 | 83/93 |
| 2020 | ONCOLOGY | SCIE | Q4 | Q3 | 227/242 |
| 2020 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | Q3 | 237/276 |
| 2019 | INFECTIOUS DISEASES | SCIE | Q4 | Q3 | 78/92 |
| 2019 | ONCOLOGY | SCIE | Q4 | Q3 | 222/244 |
| 2019 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | Q3 | 225/271 |
| 2018 | INFECTIOUS DISEASES | SCIE | Q4 | Q3 | 73/89 |
| 2018 | ONCOLOGY | SCIE | Q4 | Q3 | 207/230 |
| 2018 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | Q3 | 210/267 |
| 2017 | INFECTIOUS DISEASES | SCIE | Q4 | Q4 | 74/88 |
| 2017 | ONCOLOGY | SCIE | Q4 | Q4 | 203/223 |
| 2017 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | Q4 | 213/261 |
| 2016 | INFECTIOUS DISEASES | SCIE | Q4 | — | 68/84 |
| 2016 | ONCOLOGY | SCIE | Q4 | — | 182/217 |
| 2016 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | — | 196/257 |
| 2015 | INFECTIOUS DISEASES | SCIE | Q4 | — | 67/83 |
| 2015 | ONCOLOGY | SCIE | Q4 | — | 185/213 |
| 2015 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | — | 203/255 |
| 2014 | INFECTIOUS DISEASES | SCIE | Q4 | — | 60/78 |
| 2014 | ONCOLOGY | SCIE | Q4 | — | 169/211 |
| 2014 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 175/255 |
| 2013 | ONCOLOGY | SCIE | Q4 | — | 179/203 |
| 2013 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | — | 204/256 |
| 2012 | ONCOLOGY | SCIE | Q4 | — | 182/197 |
| 2012 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | — | 219/261 |
| 2011 | ONCOLOGY | SCIE | Q4 | — | 163/196 |
| 2011 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | — | 203/261 |
| 2010 | ONCOLOGY | SCIE | Q4 | — | 152/185 |
| 2010 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | — | 193/252 |
| 2009 | ONCOLOGY | SCIE | Q4 | — | 136/166 |
| 2009 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | — | 184/237 |
| 2008 | ONCOLOGY | SCIE | Q4 | — | 137/143 |
| 2008 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | — | 187/219 |
| 2007 | ONCOLOGY | SCIE | Q4 | — | 124/132 |
| 2007 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | — | 170/205 |
| 2006 | ONCOLOGY | SCIE | Q4 | — | 109/127 |
| 2006 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 137/199 |
| 2005 | ONCOLOGY | SCIE | Q4 | — | 106/123 |
| 2005 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 143/193 |
| 2004 | ONCOLOGY | SCIE | Q4 | — | 102/123 |
| 2004 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 134/187 |
| 2003 | ONCOLOGY | SCIE | Q4 | — | 101/120 |
| 2003 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 132/185 |
| 2002 | ONCOLOGY | SCIE | Q4 | — | 97/114 |
| 2002 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 139/188 |
| 2001 | ONCOLOGY | SCIE | Q3 | — | 79/107 |
| 2001 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 106/186 |
| 2000 | ONCOLOGY | SCIE | Q4 | — | 83/103 |
| 2000 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 121/181 |
| 1999 | ONCOLOGY | SCIE | Q4 | — | 83/105 |
| 1999 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 121/175 |
| 1998 | ONCOLOGY | SCIE | Q4 | — | 82/104 |
| 1998 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 123/178 |
| 1997 | ONCOLOGY | SCIE | Q4 | — | 92/102 |
| 1997 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | — | 148/157 |